Gene therapy for rare Sugar-Storage disease shows promise in Long-Term safety check
NCT ID NCT03970278
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study checked the long-term safety of a one-time gene therapy (DTX401) in 12 adults with glycogen storage disease type Ia, a rare condition that causes dangerously low blood sugar. Researchers monitored side effects and how well the therapy helped control blood sugar levels over time. The goal was to see if the treatment remains safe and effective in the long run.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLYCOGEN STORAGE DISEASE TYPE IA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruna, 15706, Spain
-
Michigan Medicine University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Montreal Children Hospital, McGill University Health Centre
Montreal, Quebec, H4A3J1, Canada
-
UCONN Health
Farmington, Connecticut, 06030-3213, United States
-
University Medical Center Groningen
Groningen, 9700RB, Netherlands
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can home tests replace lab draws for rare disease patients?
- Can a simple Finger-Stick replace lab tests for rare metabolic disease?
- Gene therapy breakthrough aims to control rare metabolic disease
- Gene therapy could free GSD ia patients from constant cornstarch
- GSDIa patients monitored for 10 years after gene therapy